{"id":"NCT02324569","sponsor":"Takeda","briefTitle":"A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 4, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 Diabetes","officialTitle":"A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative Study and a Phase 4, Multicenter, Open-label, Long-term Study to Evaluate the Safety and Efficacy of SYR-472 When Orally Administered at a Dose of 100 mg Once Weekly as an add-on to Insulin Therapy in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Treatment With Insulin Preparations in Addition to Diet and/or Exercise Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-12-27","primaryCompletion":"2016-12-28","completion":"2016-12-28","firstPosted":"2014-12-24","resultsPosted":"2019-02-11","lastUpdate":"2023-12-12"},"enrollment":240,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"SYR-472","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Treatment Group I","type":"EXPERIMENTAL"},{"label":"Treatment Group II","type":"EXPERIMENTAL"}],"summary":"The purposes of this study is to evaluate the efficacy and safety of SYR-472 when administered at a dose of 100 mg once weekly as an add-on to insulin therapy compared with placebo in patients with type 2 diabetes mellitus and inadequate glycemic control despite treatment with insulin preparations in addition to diet and/or exercise therapy; and to evaluate the long-term efficacy and safety of SYR-472 when administered at a dose of 100 mg once weekly as an add-on to insulin therapy in patients with type 2 diabetes mellitus and inadequate glycemic control despite treatment with insulin preparations in addition to diet and/or exercise therapy.","primaryOutcome":{"measure":"Change in HbA1c From Baseline at the End of Treatment Period I (End of Treatment Period I - End of the Screening Period)","timeFrame":"End of the screening period (Week 0) and End of Treatment Period I (Up to Week 12)","effectByArm":[{"arm":"Treatment Group I","deltaMin":-0.56,"sd":0.07},{"arm":"Treatment Group II","deltaMin":0.07,"sd":0.067}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":65,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":116},"commonTop":["Nasopharyngitis","Hypoglycaemia","Upper respiratory tract inflammation","Back pain","Dental caries"]}}